Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02409342 · OUTCOME

Maximum Observed Serum Concentration (Cmax) of Atezolizumab

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] · Source last updated 2023-03-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
micrograms per milliliter (μg/ mL)
Interval / dispersion
Standard Deviation
Time frame
0 hour (predose) and 30 minutes after atezolizumab infusion on Day 1 (infusion duration = up to 1 hour)

Analysis population: PK analyses was based on PK observations from all randomized participants who received atezolizumab and provided at least one PK sample that was evaluable.

Groups in this outcome

Atezolizumab

Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab270

Reported measurements

Source class 1
Values in micrograms per milliliter (μg/ mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Atezolizumab411163Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        163
        value
        411
denoms
  1. counts
    1. group Id
      OG000
      value
      270
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
    id
    OG000
    title
    Atezolizumab
param Type
MEAN
population Description
PK analyses was based on PK observations from all randomized participants who received atezolizumab and provided at least one PK sample that was evaluable.
reporting Status
POSTED
time Frame
0 hour (predose) and 30 minutes after atezolizumab infusion on Day 1 (infusion duration = up to 1 hour)
title
Maximum Observed Serum Concentration (Cmax) of Atezolizumab
type
SECONDARY
unit Of Measure
micrograms per milliliter (μg/ mL)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice